secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001213900-24-100527
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed publishes study on cannabinol anti-inflammatory effects in skin diseases
------------------------------------------------------------------------------

- Study published in peer-reviewed journal Biofactors; sponsored by InMed and led by Dr. Maccarrone.
- CBN prevented keratinocyte inflammation via TRPV1 and modulated endocannabinoid system enzymes.
- CBN reduced pro-inflammatory cytokines (IL-8, IL-12, IL-31) and increased anti-inflammatory IL-10.
- Potential applications for psoriasis, atopic dermatitis, and pruritus; supports cosmetic and therapeutic use.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024100527/0001213900-24-100527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024100527/ea0222020-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-100527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer